Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit

Nicholas D. Klemen, Gang Han, Stanley P. Leong, Mohammed Kashani-Sabet, John Vetto, Richard White, Schlomo Schneebaum, Barbara Pockaj, Nicola Mozzillo, Kim Charney, Harald Hoekstra, Vernon K. Sondak, Jane L. Messina, Jonathan S. Zager, Dale Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Completion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND). Methods: Positive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma-specific survival (MSS). Results: There were 953 positive SLN patients of whom 831 (87%) had CLND. Positive CLND was seen in 141 (17%) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No-CLND) in 122 of 953 positive SLN cases (13%), of whom 100 had follow-up and 18 (18%) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No-CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No-CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis. Conclusions: Performance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.

Original languageEnglish (US)
Pages (from-to)1053-1059
Number of pages7
JournalJournal of surgical oncology
Volume119
Issue number8
DOIs
StatePublished - Jun 15 2019

Fingerprint

Lymph Node Excision
Melanoma
Biopsy
Survival
cyhalothrin
Recurrence
Neoplasm Metastasis
Sentinel Lymph Node
Databases

Keywords

  • completion lymphadenectomy
  • melanoma
  • nonsentinel node metastasis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. / Klemen, Nicholas D.; Han, Gang; Leong, Stanley P.; Kashani-Sabet, Mohammed; Vetto, John; White, Richard; Schneebaum, Schlomo; Pockaj, Barbara; Mozzillo, Nicola; Charney, Kim; Hoekstra, Harald; Sondak, Vernon K.; Messina, Jane L.; Zager, Jonathan S.; Han, Dale.

In: Journal of surgical oncology, Vol. 119, No. 8, 15.06.2019, p. 1053-1059.

Research output: Contribution to journalArticle

Klemen, ND, Han, G, Leong, SP, Kashani-Sabet, M, Vetto, J, White, R, Schneebaum, S, Pockaj, B, Mozzillo, N, Charney, K, Hoekstra, H, Sondak, VK, Messina, JL, Zager, JS & Han, D 2019, 'Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit', Journal of surgical oncology, vol. 119, no. 8, pp. 1053-1059. https://doi.org/10.1002/jso.25444
Klemen, Nicholas D. ; Han, Gang ; Leong, Stanley P. ; Kashani-Sabet, Mohammed ; Vetto, John ; White, Richard ; Schneebaum, Schlomo ; Pockaj, Barbara ; Mozzillo, Nicola ; Charney, Kim ; Hoekstra, Harald ; Sondak, Vernon K. ; Messina, Jane L. ; Zager, Jonathan S. ; Han, Dale. / Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. In: Journal of surgical oncology. 2019 ; Vol. 119, No. 8. pp. 1053-1059.
@article{a790fb8bff2749a2aee9b95b6be7fe99,
title = "Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit",
abstract = "Background: Completion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND). Methods: Positive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma-specific survival (MSS). Results: There were 953 positive SLN patients of whom 831 (87{\%}) had CLND. Positive CLND was seen in 141 (17{\%}) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No-CLND) in 122 of 953 positive SLN cases (13{\%}), of whom 100 had follow-up and 18 (18{\%}) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No-CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No-CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis. Conclusions: Performance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.",
keywords = "completion lymphadenectomy, melanoma, nonsentinel node metastasis",
author = "Klemen, {Nicholas D.} and Gang Han and Leong, {Stanley P.} and Mohammed Kashani-Sabet and John Vetto and Richard White and Schlomo Schneebaum and Barbara Pockaj and Nicola Mozzillo and Kim Charney and Harald Hoekstra and Sondak, {Vernon K.} and Messina, {Jane L.} and Zager, {Jonathan S.} and Dale Han",
year = "2019",
month = "6",
day = "15",
doi = "10.1002/jso.25444",
language = "English (US)",
volume = "119",
pages = "1053--1059",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit

AU - Klemen, Nicholas D.

AU - Han, Gang

AU - Leong, Stanley P.

AU - Kashani-Sabet, Mohammed

AU - Vetto, John

AU - White, Richard

AU - Schneebaum, Schlomo

AU - Pockaj, Barbara

AU - Mozzillo, Nicola

AU - Charney, Kim

AU - Hoekstra, Harald

AU - Sondak, Vernon K.

AU - Messina, Jane L.

AU - Zager, Jonathan S.

AU - Han, Dale

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Background: Completion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND). Methods: Positive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma-specific survival (MSS). Results: There were 953 positive SLN patients of whom 831 (87%) had CLND. Positive CLND was seen in 141 (17%) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No-CLND) in 122 of 953 positive SLN cases (13%), of whom 100 had follow-up and 18 (18%) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No-CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No-CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis. Conclusions: Performance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.

AB - Background: Completion lymph node dissection (CLND) for sentinel lymph node (SLN) disease in melanoma patients is debated. We evaluated the impact of CLND on survival and assessed for predictors of nonsentinel node metastasis (positive CLND). Methods: Positive SLN melanoma patients were retrospectively identified in the Sentinel Lymph Node Working Group database. Clinicopathological factors were correlated with CLND status, overall survival (OS), and melanoma-specific survival (MSS). Results: There were 953 positive SLN patients of whom 831 (87%) had CLND. Positive CLND was seen in 141 (17%) cases and was associated with worse OS and MSS (both P < 0.001). CLND was not performed (No-CLND) in 122 of 953 positive SLN cases (13%), of whom 100 had follow-up and 18 (18%) developed a nodal recurrence (NR). No significant differences in OS and MSS were seen comparing CLND with No-CLND (P = 0.084, P = 0.161, respectively) and comparing positive CLND with No-CLND NR patients (P = 0.565, P = 0.998, respectively). Gender, primary site, ulceration, and number of positive SLNs were correlated with nonsentinel node metastasis. Conclusions: Performance of CLND provides prognostic information but is not associated with a survival benefit. Clinical variables can predict a positive CLND in patients who may be at high risk of recurrence.

KW - completion lymphadenectomy

KW - melanoma

KW - nonsentinel node metastasis

UR - http://www.scopus.com/inward/record.url?scp=85066107868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066107868&partnerID=8YFLogxK

U2 - 10.1002/jso.25444

DO - 10.1002/jso.25444

M3 - Article

C2 - 30883771

AN - SCOPUS:85066107868

VL - 119

SP - 1053

EP - 1059

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 8

ER -